-
1دورية أكاديمية
المؤلفون: Mahmoudi, Khalil, Galea, Roberto, Elhadad, Simon, Temperli, Fabrice, Sebag, Frederic, Gräni, Christoph, Rezine, Zhor, Roten, Laurent, Landolff, Quentin, Brugger, Nicolas, Masri, Alaa, Räber, Lorenz, Amabile, Nicolas
المصدر: Mahmoudi, Khalil; Galea, Roberto; Elhadad, Simon; Temperli, Fabrice; Sebag, Frederic; Gräni, Christoph; Rezine, Zhor; Roten, Laurent; Landolff, Quentin; Brugger, Nicolas; Masri, Alaa; Räber, Lorenz; Amabile, Nicolas (2023). Computed Tomography Scan Evidence for Left Atrial Appendage Short-Term Remodeling Following Percutaneous Occlusion: Impact of Device Oversizing. Journal of the American Heart Association, 12(17), e030037. American Heart Association 10.1161/JAHA.123.030037
مصطلحات موضوعية: 610 Medicine & health
الوصف: Background The interrelationships between left atrial appendage (LAA) dimensions and device following implantation are unknown. We aimed to analyze the impact of Watchman device implantation on LAA dimensions following its percutaneous closure and potential predictors of remodeling. Methods and Results All consecutive LAA closure procedures performed at 2 centers between November 2017 and December 2020 were included in the WATCH-DUAL (Watchman 2.5 Versus Watchman FLX in a Dual-Center Left Atrial Appendage Closure Cohort) registry. This study included patients who had pre- and postintervention computed tomography scan analysis. The LAA and device dimensions were measured in a centralized core lab by 3-dimensional computed tomography scan reconstruction methods, focusing on the device landing zone. This analysis included 104 patients (age, 76.0 [range, 72.0-83.0] years; 72% men; 53% Watchman FLX; 47% Watchman 2.5). The baseline characteristics were comparable between Watchman 2.5 and Watchman FLX groups, except for the higher use of oversizing in the latter group. The median delay for computed tomography control was 49 (range, 43-64) days. The landing zone area (median, 446 [range, 363-523] versus 290 [222-366] mm2; P<0.001) and minimal diameter (median, 23.0 [range, 20.7-24.8] versus 16.7 [14.7-19.4] mm; P<0.001) significantly increased after implantation. The absolute (median, 157 [range, 98-220] versus 85 [18-148] mm2, P<0.001) and relative (median, 50% [range, 32%-79%] versus 26% [4%-50%]; P<0.001) increases in landing zone area were more pronounced in patients with oversized device. Baseline LAA dimensions were smaller, landing zone eccentricity larger, and oversized device more frequent in patients with significant overexpansion compared with the others. Conclusions LAA dimensions increased at the site of the Watchman prosthesis after implantation, suggesting a local positive remodeling after the procedure. This phenomenon was more pronounced in the case of oversized devices.
وصف الملف: application/pdf
العلاقة: https://boris.unibe.ch/185698Test/
-
2دورية أكاديمية
المؤلفون: Belle, Eric Van, Vincent, Flavien, Labreuche, Julien, Auffret, Vincent, Debry, Nicolas, Lefèvre, Thierry, Eltchaninoff, Helene, Manigold, Thibaut, Gilard, Martine, Verhoye, Jean-Phillipe, Himbert, Dominique, Koning, Rene, Collet, Jean-Phillipe, Leprince, Pascal, Teiger, Emmanuel, Duhamel, Alain, Cosenza, Alessandro, Schurtz, Guillaume, Porouchani, Sina, Lattuca, Benoit, Robin, Emmanuel, Coisne, Augustin, Modine, Thomas, Richardson, Marjorie, Joly, Patrick, Rioufol, Gilles, Ghostine, Said, Bar, Olivier, Amabile, Nicolas, Champagnac, Didier, Ohlmann, Patrick, Meneveau, Nicolas, Lhermusier, Thibaut, Leroux, Lionel, Leclercq, Florence, Gandet, Thomas, Pinaud, Frédéric, Cuisset, Thomas, Motreff, Pascal, Souteyrand, Géraud, Iung, Bernard, Folliguet, Thierry, Commeau, Philippe, Cayla, Guillaume, Bayet, Gilles, Darremont, Olivier, Spaulding, Christian, Breton, Hervé Le, Delhaye, Cédric
المساهمون: Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC-IT Rennes, Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou -Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Pharmacologie des Dysfonctionnements Endotheliaux et Myocardiques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ITX - unité de recherche de l'institut du thorax (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Optimisation des régulations physiologiques (ORPHY (EA 4324)), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), CIC CHU Lyon (inserm), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Cardiologie Hôpital de la Timone - APHM, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Timone CHU - APHM (TIMONE), CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand
المصدر: ISSN: 0009-7322.
مصطلحات موضوعية: aortic valve insufficiency, aortic valve stenosis, heart valve disease, mortality, transcatheter aortic valve replacement, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
الوصف: International audience ; Background - No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end points after transcatheter aortic valve replacement has been conducted to date. Methods - From January 2013 to December 2015, the FRANCE-TAVI nationwide registry (Registry of Aortic Valve Bioprostheses Established by Catheter) included 12 141 patients undergoing BE-THV (Edwards, n=8038) or SE-THV (Medtronic, n=4103) for treatment of native aortic stenosis. Long term mortality status was available in all patients (median 20 months; interquartile range, 14 to 30). Patients treated with BE-THV (n=3910) were successfully matched 1:1 with 3910 patients treated with SE-THV by using propensity score (25 clinical, anatomical, and procedural variables) and by date of the procedure (within 3 months). The first coprimary outcome was ≥ moderate occurrence of paravalvular regurgitation or in-hospital mortality, or both. The second coprimary outcome was 2-year all-cause mortality. Results - In propensity-matched analyses, the incidence of the first coprimary outcome was higher with SE-THV (19.8%) compared with BE-THV (11.9%; relative risk, 1.68 [95% CI, 1.46-1.91]; <0.0001). Each component of the outcome was also higher in patients receiving SE-THV: ≥ moderate paravalvular regurgitation (15.5% versus 8.3%; relative risk, 1.90 [95% CI, 1.63-2.22]; <0.0001) and in hospital mortality (5.6% versus 4.2%; relative risk, 1.34 [95% CI, 1.07-1.66]; =0.01). During follow up, all cause mortality occurred in 899 patients treated with SE-THV (2-year mortality, 29.8%) and in 801 patients treated with BE-THV (2-year mortality, 26.6%; hazard ratio, 1.17 [95% CI, 1.06-1.29]; =0.003). Similar results were found using inverse probability of treatment weighting using propensity score analysis. Conclusion - The present study suggests that use of SE-THV was associated with a higher risk of paravalvular regurgitation and higher in-hospital and 2-year mortality ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31736356; hal-02472206; https://univ-rennes.hal.science/hal-02472206Test; https://univ-rennes.hal.science/hal-02472206/documentTest; https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest; PUBMED: 31736356; WOS: 000528028200007
الإتاحة: https://doi.org/10.1161/CIRCULATIONAHA.119.043785Test
https://univ-rennes.hal.science/hal-02472206Test
https://univ-rennes.hal.science/hal-02472206/documentTest
https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest -
3دورية أكاديمية
المؤلفون: Belle, Eric Van, Vincent, Flavien, Labreuche, Julien, Auffret, Vincent, Debry, Nicolas, Lefèvre, Thierry, Eltchaninoff, Helene, Manigold, Thibaut, Gilard, Martine, Verhoye, Jean-Phillipe, Himbert, Dominique, Koning, Rene, Collet, Jean-Phillipe, Leprince, Pascal, Teiger, Emmanuel, Duhamel, Alain, Cosenza, Alessandro, Schurtz, Guillaume, Porouchani, Sina, Lattuca, Benoit, Robin, Emmanuel, Coisne, Augustin, Modine, Thomas, Richardson, Marjorie, Joly, Patrick, Rioufol, Gilles, Ghostine, Said, Bar, Olivier, Amabile, Nicolas, Champagnac, Didier, Ohlmann, Patrick, Meneveau, Nicolas, Lhermusier, Thibaut, Leroux, Lionel, Leclercq, Florence, Gandet, Thomas, Pinaud, Frédéric, Cuisset, Thomas, Motreff, Pascal, Souteyrand, Géraud, Iung, Bernard, Folliguet, Thierry, Commeau, Philippe, Cayla, Guillaume, Bayet, Gilles, Darremont, Olivier, Spaulding, Christian, Breton, Hervé Le, Delhaye, Cédric
المساهمون: Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC-IT Rennes, Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou -Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Pharmacologie des Dysfonctionnements Endotheliaux et Myocardiques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ITX - unité de recherche de l'institut du thorax (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Optimisation des régulations physiologiques (ORPHY (EA 4324)), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), CIC CHU Lyon (inserm), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Cardiologie Hôpital de la Timone - APHM, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Timone CHU - APHM (TIMONE), CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand
المصدر: ISSN: 0009-7322.
مصطلحات موضوعية: aortic valve insufficiency, aortic valve stenosis, heart valve disease, mortality, transcatheter aortic valve replacement, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
الوصف: International audience ; Background - No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end points after transcatheter aortic valve replacement has been conducted to date. Methods - From January 2013 to December 2015, the FRANCE-TAVI nationwide registry (Registry of Aortic Valve Bioprostheses Established by Catheter) included 12 141 patients undergoing BE-THV (Edwards, n=8038) or SE-THV (Medtronic, n=4103) for treatment of native aortic stenosis. Long term mortality status was available in all patients (median 20 months; interquartile range, 14 to 30). Patients treated with BE-THV (n=3910) were successfully matched 1:1 with 3910 patients treated with SE-THV by using propensity score (25 clinical, anatomical, and procedural variables) and by date of the procedure (within 3 months). The first coprimary outcome was ≥ moderate occurrence of paravalvular regurgitation or in-hospital mortality, or both. The second coprimary outcome was 2-year all-cause mortality. Results - In propensity-matched analyses, the incidence of the first coprimary outcome was higher with SE-THV (19.8%) compared with BE-THV (11.9%; relative risk, 1.68 [95% CI, 1.46-1.91]; <0.0001). Each component of the outcome was also higher in patients receiving SE-THV: ≥ moderate paravalvular regurgitation (15.5% versus 8.3%; relative risk, 1.90 [95% CI, 1.63-2.22]; <0.0001) and in hospital mortality (5.6% versus 4.2%; relative risk, 1.34 [95% CI, 1.07-1.66]; =0.01). During follow up, all cause mortality occurred in 899 patients treated with SE-THV (2-year mortality, 29.8%) and in 801 patients treated with BE-THV (2-year mortality, 26.6%; hazard ratio, 1.17 [95% CI, 1.06-1.29]; =0.003). Similar results were found using inverse probability of treatment weighting using propensity score analysis. Conclusion - The present study suggests that use of SE-THV was associated with a higher risk of paravalvular regurgitation and higher in-hospital and 2-year mortality ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31736356; hal-02472206; https://univ-rennes.hal.science/hal-02472206Test; https://univ-rennes.hal.science/hal-02472206/documentTest; https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest; PUBMED: 31736356; WOS: 000528028200007
الإتاحة: https://doi.org/10.1161/CIRCULATIONAHA.119.043785Test
https://univ-rennes.hal.science/hal-02472206Test
https://univ-rennes.hal.science/hal-02472206/documentTest
https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest -
4دورية أكاديمية
المؤلفون: Belle, Eric Van, Vincent, Flavien, Labreuche, Julien, Auffret, Vincent, Debry, Nicolas, Lefèvre, Thierry, Eltchaninoff, Helene, Manigold, Thibaut, Gilard, Martine, Verhoye, Jean-Phillipe, Himbert, Dominique, Koning, Rene, Collet, Jean-Phillipe, Leprince, Pascal, Teiger, Emmanuel, Duhamel, Alain, Cosenza, Alessandro, Schurtz, Guillaume, Porouchani, Sina, Lattuca, Benoit, Robin, Emmanuel, Coisne, Augustin, Modine, Thomas, Richardson, Marjorie, Joly, Patrick, Rioufol, Gilles, Ghostine, Said, Bar, Olivier, Amabile, Nicolas, Champagnac, Didier, Ohlmann, Patrick, Meneveau, Nicolas, Lhermusier, Thibaut, Leroux, Lionel, Leclercq, Florence, Gandet, Thomas, Pinaud, Frédéric, Cuisset, Thomas, Motreff, Pascal, Souteyrand, Géraud, Iung, Bernard, Folliguet, Thierry, Commeau, Philippe, Cayla, Guillaume, Bayet, Gilles, Darremont, Olivier, Spaulding, Christian, Breton, Hervé Le, Delhaye, Cédric
المساهمون: Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC-IT Rennes, Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou -Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Pharmacologie des Dysfonctionnements Endotheliaux et Myocardiques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ITX - unité de recherche de l'institut du thorax (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Optimisation des régulations physiologiques (ORPHY (EA 4324)), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), CIC CHU Lyon (inserm), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Cardiologie Hôpital de la Timone - APHM, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Timone CHU - APHM (TIMONE), CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand
المصدر: ISSN: 0009-7322.
مصطلحات موضوعية: aortic valve insufficiency, aortic valve stenosis, heart valve disease, mortality, transcatheter aortic valve replacement, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
الوصف: International audience ; Background - No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end points after transcatheter aortic valve replacement has been conducted to date. Methods - From January 2013 to December 2015, the FRANCE-TAVI nationwide registry (Registry of Aortic Valve Bioprostheses Established by Catheter) included 12 141 patients undergoing BE-THV (Edwards, n=8038) or SE-THV (Medtronic, n=4103) for treatment of native aortic stenosis. Long term mortality status was available in all patients (median 20 months; interquartile range, 14 to 30). Patients treated with BE-THV (n=3910) were successfully matched 1:1 with 3910 patients treated with SE-THV by using propensity score (25 clinical, anatomical, and procedural variables) and by date of the procedure (within 3 months). The first coprimary outcome was ≥ moderate occurrence of paravalvular regurgitation or in-hospital mortality, or both. The second coprimary outcome was 2-year all-cause mortality. Results - In propensity-matched analyses, the incidence of the first coprimary outcome was higher with SE-THV (19.8%) compared with BE-THV (11.9%; relative risk, 1.68 [95% CI, 1.46-1.91]; <0.0001). Each component of the outcome was also higher in patients receiving SE-THV: ≥ moderate paravalvular regurgitation (15.5% versus 8.3%; relative risk, 1.90 [95% CI, 1.63-2.22]; <0.0001) and in hospital mortality (5.6% versus 4.2%; relative risk, 1.34 [95% CI, 1.07-1.66]; =0.01). During follow up, all cause mortality occurred in 899 patients treated with SE-THV (2-year mortality, 29.8%) and in 801 patients treated with BE-THV (2-year mortality, 26.6%; hazard ratio, 1.17 [95% CI, 1.06-1.29]; =0.003). Similar results were found using inverse probability of treatment weighting using propensity score analysis. Conclusion - The present study suggests that use of SE-THV was associated with a higher risk of paravalvular regurgitation and higher in-hospital and 2-year mortality ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31736356; hal-02472206; https://univ-rennes.hal.science/hal-02472206Test; https://univ-rennes.hal.science/hal-02472206/documentTest; https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest; PUBMED: 31736356; WOS: 000528028200007
الإتاحة: https://doi.org/10.1161/CIRCULATIONAHA.119.043785Test
https://univ-rennes.hal.science/hal-02472206Test
https://univ-rennes.hal.science/hal-02472206/documentTest
https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest -
5دورية أكاديمية
المؤلفون: Belle, Eric Van, Vincent, Flavien, Labreuche, Julien, Auffret, Vincent, Debry, Nicolas, Lefèvre, Thierry, Eltchaninoff, Helene, Manigold, Thibaut, Gilard, Martine, Verhoye, Jean-Phillipe, Himbert, Dominique, Koning, Rene, Collet, Jean-Phillipe, Leprince, Pascal, Teiger, Emmanuel, Duhamel, Alain, Cosenza, Alessandro, Schurtz, Guillaume, Porouchani, Sina, Lattuca, Benoit, Robin, Emmanuel, Coisne, Augustin, Modine, Thomas, Richardson, Marjorie, Joly, Patrick, Rioufol, Gilles, Ghostine, Said, Bar, Olivier, Amabile, Nicolas, Champagnac, Didier, Ohlmann, Patrick, Meneveau, Nicolas, Lhermusier, Thibaut, Leroux, Lionel, Leclercq, Florence, Gandet, Thomas, Pinaud, Frédéric, Cuisset, Thomas, Motreff, Pascal, Souteyrand, Géraud, Iung, Bernard, Folliguet, Thierry, Commeau, Philippe, Cayla, Guillaume, Bayet, Gilles, Darremont, Olivier, Spaulding, Christian, Breton, Hervé Le, Delhaye, Cédric
المساهمون: Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC-IT Rennes, Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou -Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Pharmacologie des Dysfonctionnements Endotheliaux et Myocardiques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ITX - unité de recherche de l'institut du thorax (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Optimisation des régulations physiologiques (ORPHY (EA 4324)), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), CIC CHU Lyon (inserm), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Cardiologie Hôpital de la Timone - APHM, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Timone CHU - APHM (TIMONE), CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand
المصدر: ISSN: 0009-7322.
مصطلحات موضوعية: aortic valve insufficiency, aortic valve stenosis, heart valve disease, mortality, transcatheter aortic valve replacement, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
الوصف: International audience ; Background - No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end points after transcatheter aortic valve replacement has been conducted to date. Methods - From January 2013 to December 2015, the FRANCE-TAVI nationwide registry (Registry of Aortic Valve Bioprostheses Established by Catheter) included 12 141 patients undergoing BE-THV (Edwards, n=8038) or SE-THV (Medtronic, n=4103) for treatment of native aortic stenosis. Long term mortality status was available in all patients (median 20 months; interquartile range, 14 to 30). Patients treated with BE-THV (n=3910) were successfully matched 1:1 with 3910 patients treated with SE-THV by using propensity score (25 clinical, anatomical, and procedural variables) and by date of the procedure (within 3 months). The first coprimary outcome was ≥ moderate occurrence of paravalvular regurgitation or in-hospital mortality, or both. The second coprimary outcome was 2-year all-cause mortality. Results - In propensity-matched analyses, the incidence of the first coprimary outcome was higher with SE-THV (19.8%) compared with BE-THV (11.9%; relative risk, 1.68 [95% CI, 1.46-1.91]; <0.0001). Each component of the outcome was also higher in patients receiving SE-THV: ≥ moderate paravalvular regurgitation (15.5% versus 8.3%; relative risk, 1.90 [95% CI, 1.63-2.22]; <0.0001) and in hospital mortality (5.6% versus 4.2%; relative risk, 1.34 [95% CI, 1.07-1.66]; =0.01). During follow up, all cause mortality occurred in 899 patients treated with SE-THV (2-year mortality, 29.8%) and in 801 patients treated with BE-THV (2-year mortality, 26.6%; hazard ratio, 1.17 [95% CI, 1.06-1.29]; =0.003). Similar results were found using inverse probability of treatment weighting using propensity score analysis. Conclusion - The present study suggests that use of SE-THV was associated with a higher risk of paravalvular regurgitation and higher in-hospital and 2-year mortality ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31736356; hal-02472206; https://univ-rennes.hal.science/hal-02472206Test; https://univ-rennes.hal.science/hal-02472206/documentTest; https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest; PUBMED: 31736356; WOS: 000528028200007
الإتاحة: https://doi.org/10.1161/CIRCULATIONAHA.119.043785Test
https://univ-rennes.hal.science/hal-02472206Test
https://univ-rennes.hal.science/hal-02472206/documentTest
https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest -
6دورية أكاديمية
المؤلفون: Belle, Eric Van, Vincent, Flavien, Labreuche, Julien, Auffret, Vincent, Debry, Nicolas, Lefèvre, Thierry, Eltchaninoff, Helene, Manigold, Thibaut, Gilard, Martine, Verhoye, Jean-Phillipe, Himbert, Dominique, Koning, Rene, Collet, Jean-Phillipe, Leprince, Pascal, Teiger, Emmanuel, Duhamel, Alain, Cosenza, Alessandro, Schurtz, Guillaume, Porouchani, Sina, Lattuca, Benoit, Robin, Emmanuel, Coisne, Augustin, Modine, Thomas, Richardson, Marjorie, Joly, Patrick, Rioufol, Gilles, Ghostine, Said, Bar, Olivier, Amabile, Nicolas, Champagnac, Didier, Ohlmann, Patrick, Meneveau, Nicolas, Lhermusier, Thibaut, Leroux, Lionel, Leclercq, Florence, Gandet, Thomas, Pinaud, Frédéric, Cuisset, Thomas, Motreff, Pascal, Souteyrand, Géraud, Iung, Bernard, Folliguet, Thierry, Commeau, Philippe, Cayla, Guillaume, Bayet, Gilles, Darremont, Olivier, Spaulding, Christian, Breton, Hervé Le, Delhaye, Cédric
المساهمون: Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC-IT Rennes, Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou -Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Pharmacologie des Dysfonctionnements Endotheliaux et Myocardiques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ITX - unité de recherche de l'institut du thorax (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Optimisation des régulations physiologiques (ORPHY (EA 4324)), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), CIC CHU Lyon (inserm), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Cardiologie Hôpital de la Timone - APHM, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Timone CHU - APHM (TIMONE), CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand
المصدر: ISSN: 0009-7322.
مصطلحات موضوعية: aortic valve insufficiency, aortic valve stenosis, heart valve disease, mortality, transcatheter aortic valve replacement, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
الوصف: International audience ; Background - No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end points after transcatheter aortic valve replacement has been conducted to date. Methods - From January 2013 to December 2015, the FRANCE-TAVI nationwide registry (Registry of Aortic Valve Bioprostheses Established by Catheter) included 12 141 patients undergoing BE-THV (Edwards, n=8038) or SE-THV (Medtronic, n=4103) for treatment of native aortic stenosis. Long term mortality status was available in all patients (median 20 months; interquartile range, 14 to 30). Patients treated with BE-THV (n=3910) were successfully matched 1:1 with 3910 patients treated with SE-THV by using propensity score (25 clinical, anatomical, and procedural variables) and by date of the procedure (within 3 months). The first coprimary outcome was ≥ moderate occurrence of paravalvular regurgitation or in-hospital mortality, or both. The second coprimary outcome was 2-year all-cause mortality. Results - In propensity-matched analyses, the incidence of the first coprimary outcome was higher with SE-THV (19.8%) compared with BE-THV (11.9%; relative risk, 1.68 [95% CI, 1.46-1.91]; <0.0001). Each component of the outcome was also higher in patients receiving SE-THV: ≥ moderate paravalvular regurgitation (15.5% versus 8.3%; relative risk, 1.90 [95% CI, 1.63-2.22]; <0.0001) and in hospital mortality (5.6% versus 4.2%; relative risk, 1.34 [95% CI, 1.07-1.66]; =0.01). During follow up, all cause mortality occurred in 899 patients treated with SE-THV (2-year mortality, 29.8%) and in 801 patients treated with BE-THV (2-year mortality, 26.6%; hazard ratio, 1.17 [95% CI, 1.06-1.29]; =0.003). Similar results were found using inverse probability of treatment weighting using propensity score analysis. Conclusion - The present study suggests that use of SE-THV was associated with a higher risk of paravalvular regurgitation and higher in-hospital and 2-year mortality ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31736356; hal-02472206; https://univ-rennes.hal.science/hal-02472206Test; https://univ-rennes.hal.science/hal-02472206/documentTest; https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest; PUBMED: 31736356; WOS: 000528028200007
الإتاحة: https://doi.org/10.1161/CIRCULATIONAHA.119.043785Test
https://univ-rennes.hal.science/hal-02472206Test
https://univ-rennes.hal.science/hal-02472206/documentTest
https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest -
7دورية أكاديمية
المؤلفون: Belle, Eric Van, Vincent, Flavien, Labreuche, Julien, Auffret, Vincent, Debry, Nicolas, Lefèvre, Thierry, Eltchaninoff, Helene, Manigold, Thibaut, Gilard, Martine, Verhoye, Jean-Phillipe, Himbert, Dominique, Koning, Rene, Collet, Jean-Phillipe, Leprince, Pascal, Teiger, Emmanuel, Duhamel, Alain, Cosenza, Alessandro, Schurtz, Guillaume, Porouchani, Sina, Lattuca, Benoit, Robin, Emmanuel, Coisne, Augustin, Modine, Thomas, Richardson, Marjorie, Joly, Patrick, Rioufol, Gilles, Ghostine, Said, Bar, Olivier, Amabile, Nicolas, Champagnac, Didier, Ohlmann, Patrick, Meneveau, Nicolas, Lhermusier, Thibaut, Leroux, Lionel, Leclercq, Florence, Gandet, Thomas, Pinaud, Frédéric, Cuisset, Thomas, Motreff, Pascal, Souteyrand, Géraud, Iung, Bernard, Folliguet, Thierry, Commeau, Philippe, Cayla, Guillaume, Bayet, Gilles, Darremont, Olivier, Spaulding, Christian, Breton, Hervé Le, Delhaye, Cédric
المساهمون: Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC-IT Rennes, Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou -Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Pharmacologie des Dysfonctionnements Endotheliaux et Myocardiques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ITX - unité de recherche de l'institut du thorax (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Optimisation des régulations physiologiques (ORPHY (EA 4324)), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), CIC CHU Lyon (inserm), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Cardiologie Hôpital de la Timone - APHM, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Timone CHU - APHM (TIMONE), CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand
المصدر: ISSN: 0009-7322.
مصطلحات موضوعية: aortic valve insufficiency, aortic valve stenosis, heart valve disease, mortality, transcatheter aortic valve replacement, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
الوصف: International audience ; Background - No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end points after transcatheter aortic valve replacement has been conducted to date. Methods - From January 2013 to December 2015, the FRANCE-TAVI nationwide registry (Registry of Aortic Valve Bioprostheses Established by Catheter) included 12 141 patients undergoing BE-THV (Edwards, n=8038) or SE-THV (Medtronic, n=4103) for treatment of native aortic stenosis. Long term mortality status was available in all patients (median 20 months; interquartile range, 14 to 30). Patients treated with BE-THV (n=3910) were successfully matched 1:1 with 3910 patients treated with SE-THV by using propensity score (25 clinical, anatomical, and procedural variables) and by date of the procedure (within 3 months). The first coprimary outcome was ≥ moderate occurrence of paravalvular regurgitation or in-hospital mortality, or both. The second coprimary outcome was 2-year all-cause mortality. Results - In propensity-matched analyses, the incidence of the first coprimary outcome was higher with SE-THV (19.8%) compared with BE-THV (11.9%; relative risk, 1.68 [95% CI, 1.46-1.91]; <0.0001). Each component of the outcome was also higher in patients receiving SE-THV: ≥ moderate paravalvular regurgitation (15.5% versus 8.3%; relative risk, 1.90 [95% CI, 1.63-2.22]; <0.0001) and in hospital mortality (5.6% versus 4.2%; relative risk, 1.34 [95% CI, 1.07-1.66]; =0.01). During follow up, all cause mortality occurred in 899 patients treated with SE-THV (2-year mortality, 29.8%) and in 801 patients treated with BE-THV (2-year mortality, 26.6%; hazard ratio, 1.17 [95% CI, 1.06-1.29]; =0.003). Similar results were found using inverse probability of treatment weighting using propensity score analysis. Conclusion - The present study suggests that use of SE-THV was associated with a higher risk of paravalvular regurgitation and higher in-hospital and 2-year mortality ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31736356; hal-02472206; https://univ-rennes.hal.science/hal-02472206Test; https://univ-rennes.hal.science/hal-02472206/documentTest; https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest; PUBMED: 31736356; WOS: 000528028200007
الإتاحة: https://doi.org/10.1161/CIRCULATIONAHA.119.043785Test
https://univ-rennes.hal.science/hal-02472206Test
https://univ-rennes.hal.science/hal-02472206/documentTest
https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest -
8دورية أكاديمية
المؤلفون: Belle, Eric Van, Vincent, Flavien, Labreuche, Julien, Auffret, Vincent, Debry, Nicolas, Lefèvre, Thierry, Eltchaninoff, Helene, Manigold, Thibaut, Gilard, Martine, Verhoye, Jean-Phillipe, Himbert, Dominique, Koning, Rene, Collet, Jean-Phillipe, Leprince, Pascal, Teiger, Emmanuel, Duhamel, Alain, Cosenza, Alessandro, Schurtz, Guillaume, Porouchani, Sina, Lattuca, Benoit, Robin, Emmanuel, Coisne, Augustin, Modine, Thomas, Richardson, Marjorie, Joly, Patrick, Rioufol, Gilles, Ghostine, Said, Bar, Olivier, Amabile, Nicolas, Champagnac, Didier, Ohlmann, Patrick, Meneveau, Nicolas, Lhermusier, Thibaut, Leroux, Lionel, Leclercq, Florence, Gandet, Thomas, Pinaud, Frédéric, Cuisset, Thomas, Motreff, Pascal, Souteyrand, Géraud, Iung, Bernard, Folliguet, Thierry, Commeau, Philippe, Cayla, Guillaume, Bayet, Gilles, Darremont, Olivier, Spaulding, Christian, Breton, Hervé Le, Delhaye, Cédric
المساهمون: Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC-IT Rennes, Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou -Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Pharmacologie des Dysfonctionnements Endotheliaux et Myocardiques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ITX - unité de recherche de l'institut du thorax (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Optimisation des régulations physiologiques (ORPHY (EA 4324)), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), CIC CHU Lyon (inserm), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Cardiologie Hôpital de la Timone - APHM, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Timone CHU - APHM (TIMONE), CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand
المصدر: ISSN: 0009-7322.
مصطلحات موضوعية: aortic valve insufficiency, aortic valve stenosis, heart valve disease, mortality, transcatheter aortic valve replacement, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
الوصف: International audience ; Background - No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end points after transcatheter aortic valve replacement has been conducted to date. Methods - From January 2013 to December 2015, the FRANCE-TAVI nationwide registry (Registry of Aortic Valve Bioprostheses Established by Catheter) included 12 141 patients undergoing BE-THV (Edwards, n=8038) or SE-THV (Medtronic, n=4103) for treatment of native aortic stenosis. Long term mortality status was available in all patients (median 20 months; interquartile range, 14 to 30). Patients treated with BE-THV (n=3910) were successfully matched 1:1 with 3910 patients treated with SE-THV by using propensity score (25 clinical, anatomical, and procedural variables) and by date of the procedure (within 3 months). The first coprimary outcome was ≥ moderate occurrence of paravalvular regurgitation or in-hospital mortality, or both. The second coprimary outcome was 2-year all-cause mortality. Results - In propensity-matched analyses, the incidence of the first coprimary outcome was higher with SE-THV (19.8%) compared with BE-THV (11.9%; relative risk, 1.68 [95% CI, 1.46-1.91]; <0.0001). Each component of the outcome was also higher in patients receiving SE-THV: ≥ moderate paravalvular regurgitation (15.5% versus 8.3%; relative risk, 1.90 [95% CI, 1.63-2.22]; <0.0001) and in hospital mortality (5.6% versus 4.2%; relative risk, 1.34 [95% CI, 1.07-1.66]; =0.01). During follow up, all cause mortality occurred in 899 patients treated with SE-THV (2-year mortality, 29.8%) and in 801 patients treated with BE-THV (2-year mortality, 26.6%; hazard ratio, 1.17 [95% CI, 1.06-1.29]; =0.003). Similar results were found using inverse probability of treatment weighting using propensity score analysis. Conclusion - The present study suggests that use of SE-THV was associated with a higher risk of paravalvular regurgitation and higher in-hospital and 2-year mortality ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31736356; hal-02472206; https://univ-rennes.hal.science/hal-02472206Test; https://univ-rennes.hal.science/hal-02472206/documentTest; https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest; PUBMED: 31736356; WOS: 000528028200007
الإتاحة: https://doi.org/10.1161/CIRCULATIONAHA.119.043785Test
https://univ-rennes.hal.science/hal-02472206Test
https://univ-rennes.hal.science/hal-02472206/documentTest
https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest -
9دورية أكاديمية
المؤلفون: Belle, Eric Van, Vincent, Flavien, Labreuche, Julien, Auffret, Vincent, Debry, Nicolas, Lefèvre, Thierry, Eltchaninoff, Helene, Manigold, Thibaut, Gilard, Martine, Verhoye, Jean-Phillipe, Himbert, Dominique, Koning, Rene, Collet, Jean-Phillipe, Leprince, Pascal, Teiger, Emmanuel, Duhamel, Alain, Cosenza, Alessandro, Schurtz, Guillaume, Porouchani, Sina, Lattuca, Benoit, Robin, Emmanuel, Coisne, Augustin, Modine, Thomas, Richardson, Marjorie, Joly, Patrick, Rioufol, Gilles, Ghostine, Said, Bar, Olivier, Amabile, Nicolas, Champagnac, Didier, Ohlmann, Patrick, Meneveau, Nicolas, Lhermusier, Thibaut, Leroux, Lionel, Leclercq, Florence, Gandet, Thomas, Pinaud, Frédéric, Cuisset, Thomas, Motreff, Pascal, Souteyrand, Géraud, Iung, Bernard, Folliguet, Thierry, Commeau, Philippe, Cayla, Guillaume, Bayet, Gilles, Darremont, Olivier, Spaulding, Christian, Breton, Hervé Le, Delhaye, Cédric
المساهمون: Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire Lille (CHRU Lille), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire Lille (CHRU Lille), Centre Hospitalier Régional Universitaire Lille (CHRU Lille), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC-IT Rennes, Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou Rennes, Pharmacologie des Dysfonctionnements Endotheliaux et Myocardiques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Optimisation des régulations physiologiques (ORPHY (EA 4324)), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), CIC CHU Lyon (inserm), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Cardiologie Hôpital de la Timone - APHM, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone CHU - APHM (TIMONE), CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand
المصدر: ISSN: 0009-7322.
مصطلحات موضوعية: aortic valve insufficiency, aortic valve stenosis, heart valve disease, mortality, transcatheter aortic valve replacement, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
الوصف: International audience ; Background - No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end points after transcatheter aortic valve replacement has been conducted to date. Methods - From January 2013 to December 2015, the FRANCE-TAVI nationwide registry (Registry of Aortic Valve Bioprostheses Established by Catheter) included 12 141 patients undergoing BE-THV (Edwards, n=8038) or SE-THV (Medtronic, n=4103) for treatment of native aortic stenosis. Long term mortality status was available in all patients (median 20 months; interquartile range, 14 to 30). Patients treated with BE-THV (n=3910) were successfully matched 1:1 with 3910 patients treated with SE-THV by using propensity score (25 clinical, anatomical, and procedural variables) and by date of the procedure (within 3 months). The first coprimary outcome was ≥ moderate occurrence of paravalvular regurgitation or in-hospital mortality, or both. The second coprimary outcome was 2-year all-cause mortality. Results - In propensity-matched analyses, the incidence of the first coprimary outcome was higher with SE-THV (19.8%) compared with BE-THV (11.9%; relative risk, 1.68 [95% CI, 1.46-1.91]; <0.0001). Each component of the outcome was also higher in patients receiving SE-THV: ≥ moderate paravalvular regurgitation (15.5% versus 8.3%; relative risk, 1.90 [95% CI, 1.63-2.22]; <0.0001) and in hospital mortality (5.6% versus 4.2%; relative risk, 1.34 [95% CI, 1.07-1.66]; =0.01). During follow up, all cause mortality occurred in 899 patients treated with SE-THV (2-year mortality, 29.8%) and in 801 patients treated with BE-THV (2-year mortality, 26.6%; hazard ratio, 1.17 [95% CI, 1.06-1.29]; =0.003). Similar results were found using inverse probability of treatment weighting using propensity score analysis. Conclusion - The present study suggests that use of SE-THV was associated with a higher risk of paravalvular regurgitation and higher in-hospital and 2-year mortality ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31736356; hal-02472206; https://univ-rennes.hal.science/hal-02472206Test; https://univ-rennes.hal.science/hal-02472206/documentTest; https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest; PUBMED: 31736356; WOS: 000528028200007
الإتاحة: https://doi.org/10.1161/CIRCULATIONAHA.119.043785Test
https://univ-rennes.hal.science/hal-02472206Test
https://univ-rennes.hal.science/hal-02472206/documentTest
https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest -
10دورية أكاديمية
المؤلفون: Belle, Eric Van, Vincent, Flavien, Labreuche, Julien, Auffret, Vincent, Debry, Nicolas, Lefèvre, Thierry, Eltchaninoff, Helene, Manigold, Thibaut, Gilard, Martine, Verhoye, Jean-Phillipe, Himbert, Dominique, Koning, Rene, Collet, Jean-Phillipe, Leprince, Pascal, Teiger, Emmanuel, Duhamel, Alain, Cosenza, Alessandro, Schurtz, Guillaume, Porouchani, Sina, Lattuca, Benoit, Robin, Emmanuel, Coisne, Augustin, Modine, Thomas, Richardson, Marjorie, Joly, Patrick, Rioufol, Gilles, Ghostine, Said, Bar, Olivier, Amabile, Nicolas, Champagnac, Didier, Ohlmann, Patrick, Meneveau, Nicolas, Lhermusier, Thibaut, Leroux, Lionel, Leclercq, Florence, Gandet, Thomas, Pinaud, Frédéric, Cuisset, Thomas, Motreff, Pascal, Souteyrand, Géraud, Iung, Bernard, Folliguet, Thierry, Commeau, Philippe, Cayla, Guillaume, Bayet, Gilles, Darremont, Olivier, Spaulding, Christian, Breton, Hervé Le, Delhaye, Cédric
المساهمون: Récepteurs nucléaires, maladies cardiovasculaires et diabète - U 1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Evaluation des technologies de santé et des pratiques médicales - ULR 2694 (METRICS), Université de Lille-Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Centre Hospitalier Régional Universitaire CHU Lille (CHRU Lille), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC-IT Rennes, Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou -Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire de Rennes CHU Rennes = Rennes University Hospital Ponchaillou, Pharmacologie des Dysfonctionnements Endotheliaux et Myocardiques, Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), ITX - unité de recherche de l'institut du thorax (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Optimisation des régulations physiologiques (ORPHY (EA 4324)), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), CIC CHU Lyon (inserm), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Maladies Métaboliques et Cardiovasculaires (I2MC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Département de Cardiologie Hôpital de la Timone - APHM, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Timone CHU - APHM (TIMONE), CHU Gabriel Montpied Clermont-Ferrand, CHU Clermont-Ferrand
المصدر: ISSN: 0009-7322.
مصطلحات موضوعية: aortic valve insufficiency, aortic valve stenosis, heart valve disease, mortality, transcatheter aortic valve replacement, [SDV.IB]Life Sciences [q-bio]/Bioengineering, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system
الوصف: International audience ; Background - No randomized study powered to compare balloon expandable (BE) with self expanding (SE) transcatheter heart valves (THVs) on individual end points after transcatheter aortic valve replacement has been conducted to date. Methods - From January 2013 to December 2015, the FRANCE-TAVI nationwide registry (Registry of Aortic Valve Bioprostheses Established by Catheter) included 12 141 patients undergoing BE-THV (Edwards, n=8038) or SE-THV (Medtronic, n=4103) for treatment of native aortic stenosis. Long term mortality status was available in all patients (median 20 months; interquartile range, 14 to 30). Patients treated with BE-THV (n=3910) were successfully matched 1:1 with 3910 patients treated with SE-THV by using propensity score (25 clinical, anatomical, and procedural variables) and by date of the procedure (within 3 months). The first coprimary outcome was ≥ moderate occurrence of paravalvular regurgitation or in-hospital mortality, or both. The second coprimary outcome was 2-year all-cause mortality. Results - In propensity-matched analyses, the incidence of the first coprimary outcome was higher with SE-THV (19.8%) compared with BE-THV (11.9%; relative risk, 1.68 [95% CI, 1.46-1.91]; <0.0001). Each component of the outcome was also higher in patients receiving SE-THV: ≥ moderate paravalvular regurgitation (15.5% versus 8.3%; relative risk, 1.90 [95% CI, 1.63-2.22]; <0.0001) and in hospital mortality (5.6% versus 4.2%; relative risk, 1.34 [95% CI, 1.07-1.66]; =0.01). During follow up, all cause mortality occurred in 899 patients treated with SE-THV (2-year mortality, 29.8%) and in 801 patients treated with BE-THV (2-year mortality, 26.6%; hazard ratio, 1.17 [95% CI, 1.06-1.29]; =0.003). Similar results were found using inverse probability of treatment weighting using propensity score analysis. Conclusion - The present study suggests that use of SE-THV was associated with a higher risk of paravalvular regurgitation and higher in-hospital and 2-year mortality ...
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31736356; hal-02472206; https://univ-rennes.hal.science/hal-02472206Test; https://univ-rennes.hal.science/hal-02472206/documentTest; https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest; PUBMED: 31736356; WOS: 000528028200007
الإتاحة: https://doi.org/10.1161/CIRCULATIONAHA.119.043785Test
https://univ-rennes.hal.science/hal-02472206Test
https://univ-rennes.hal.science/hal-02472206/documentTest
https://univ-rennes.hal.science/hal-02472206/file/Van%20Belle-2019-Balloon-Expandable%20versus%20Self-Expanding%20Transcatheter%20Aortic%20Valve.pdfTest
